What do you get from the new variant? With new SARS-CoV-2 variants sometimes reviving a wave of a new Covid-19 pandemic, this has been a longstanding question on people’s minds. Now, researchers have a possible answer. Scientists now say that coronavirus variants of concern are more likely to emerge from chronic or chronic Covid patients who are immunocompromised. Such patients are unable to clear the virus, a new study strongly suggests.
more lethal: Frontiers in Virology published Findings from scientists at Emory University and the University of Oxford suggest that the coronavirus of concern from older or taller COVID patients may be more deadly and requires urgent attention, rather than developing from routine transmission among millions of humans.
earlier studies have shown that some immune-compromised people, such as those taking medications for other chronic disorders, have had an active COVID infection for a year or more.
it’s important To identify these people, the researchers focused not only on helping them treat Covid, but also on genomic surveillance of the SARS-CoV-2 virus they carry.
SARS-CoV-2As viruses evolve continuously because of mutations in the genetic code that can occur on their repeat. Typically, random mutations do not benefit the virus or raise the concerns of scientists monitoring these changes.
sometimesHowever, the mutation results in a variant of the virus that can make it more transmissible, more difficult to detect and treat, and even more lethal.
World Health Organization These first three types of anxiety are termed alpha, beta and gamma.
another secret This is why large clusters of mutations arose in VoCs. Researchers have created a mechanical, theoretical model to study the problem. The resulting model rejects the theory that anxiety types emerged from the continuous transmission of acute infections and fully supports the theory that each variant developed within an individual with a chronic infection.
Two separate studies from Kochi hospitals – Aster Medicity and Renai Medicity – published in the medical journal, stated that eight patients reported Guillain-Barré syndrome (GBS) within two weeks of receiving the Covishield vaccine, which A rare neurological disorder, but potentially serious.
There are very few case reports globally regarding GBS after covid vaccination.
The benefits of vaccination far outweigh the risks of GBS and there was no morbidity or mortality due to GBS. However, physicians need to be alert to a potential adverse event, experts say.
While seven cases were reported from Aster Medicity that occurred within two weeks of the first dose of COVID vaccination, one case reported from Renai Medicity was a 35-year-old woman who came to the hospital 13 days after the COVID vaccination. Was.
Most of the patients were middle-aged and predominantly female (female:male ratio – 7:1). Most of them developed severe GBS and required mechanical ventilatory support. Although they did recover, some took longer to recover – three to four months. more information Here
Follow the news important to you in real time. Join 3 crore news lovers.
written by: Rakesh Rai, Sushmita Chaudhary, Jayant Kalita, Prabhas K Dutta research: Rajesh Sharma